MuraroPAMariottiniAGrecoR, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder – Recommendations from ECTRIMS and the EBMT. Nat Rev Neurol2025; 21(3): 140–158.
2.
SelmajKCreeBACBarnettM, et al. Multiple sclerosis: Time for early treatment with high-efficacy drugs. J Neurol2024; 271(1): 105–115.
3.
JuntTCalzasciaTTraggiaiE, et al. Defining immune reset: Achieving sustained remission in autoimmune diseases. Nat Rev Immunol2025; 25(7): 528–541.
4.
SailorKAAgoranosGLópez-ManzanedaS, et al. Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain. Nat Med2022; 28(3): 517–527.
5.
KalincikTSharminSRoosI, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurology2023.
6.
KalincikTSharminSRoosI, et al. Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis. Brain2026; 149: 951–962.
7.
MuraroPAZitoASignoriA, et al. Effectiveness of autologous hematopoietic stem cell transplantation versus Alemtuzumab and Ocrelizumab in relapsing multiple sclerosis: A single center cohort study. Ann Neurol2025; 98(2): 294–307.
8.
MuraroPAKazmiMDe MatteisE, et al. Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK. J Neurol Neurosurg Psychiatry2026; 97: 146–155.
9.
MariottiniAMazzeoACSimonettiE, et al. Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: A comparative matched study. J Neurol Neurosurg Psychiatry2026; 97: 156–164.
10.
DasJSnowdenJABurmanJ, et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis. Mult Scler2021; 27(8): 1198–1204.
